MTM: Net profit in the third quarter was 146 million yuan, a year-on-year increase of 3.74%

MTM announced that its revenue for the third quarter was 815 million yuan, a year-on-year increase of 20.12%; net profit was 146 million yuan, a year-on-year increase of 3.74%. Revenue for the first three quarters was 2.381 billion yuan, a year-on-year increase of 18.29%; net profit was 509 million yuan, a year-on-year increase of 12.90%

MTM: Completed the repurchase of 335,100 shares

MTM announced that from April 22, 2025, to October 21, 2025, the company repurchased shares through centralized bidding, with an actual repurchase of 335,100 shares, accounting for 0.18% of the total share capital. The repurchase price range was from 62.01 yuan/share to 93.76 yuan/share, with a total amount of funds used being 30.0215 million yuan. The repurchased shares will be used for the employee stock ownership plan or equity incentives

MTM's shareholder Zhongke Investment plans to reduce its holdings by no more than 2%

According to the Zhitong Finance APP, MTM announced that its shareholder Zhongke Investment plans to reduce its holdings of the company's shares by no more than 3.7569 million shares through centralized bidding and block trading, with a planned reduction ratio of no more than 2%

This week, the concentration of institutional research has increased, with 4 companies receiving research from over a hundred institutions

This week, the concentration of institutional research increased, with 67 listed companies disclosing research records, and about 70% of the companies achieved positive returns. Haineng Technology rose over 42%, FLAC, CGWS, and HAYEUR rose over 30%, and Keystone Technology rose over 25%. MTM and AGS were researched by 183 and 180 institutions respectively, becoming the companies with the most participation in research this week

The medical device sector has risen again, with SINOMED, David Medical, MEDLANDER, and Sanxin Medtec increasing by over 10%, while Sanyou Medical and MTM also followed suit